The FDA has placed its most serious warning - called a Boxed Warning - on the non-hormonal drug fezolinetant, which is sold under the brand name Veozah.

Astellas, the drug’s manufacturer, said in a statement that patient safety is its top priority. “It’s important to note that the overall benefit-risk of Veozah has not changed and remains ...

WEDNESDAY, Dec. 18, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

Elinzanetant works similarly to Veozah, targeting a receptor known as neurokinin 3, as well as another dubbed neurokinin 1. Both receptors are involved in regulating body temperature.

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.

Veozah was approved in 2023. It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B, which plays a role in the brain’s regulation of body temperature.

Veozah was approved in 2023. It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B, which plays a role in the brain’s regulation of body temperature.